MedPath

IV NSAI Versus Nebulized Morphine Analgesia for First-line Renal Colic

Phase 1
Completed
Conditions
Renal Colic
Interventions
Drug: IV NSAI
Drug: NM
Drug: Nebulised Serum Saline
Drug: IV Serum Saline
Registration Number
NCT02156596
Lead Sponsor
University of Monastir
Brief Summary

The aim of the investigators study was to evaluate the feasibility, efficacy and safety of nebulized morphine compared with non-steroidal anti-inflammatory (NSAI)intravenously in the management of renal colic.

Determine the need for systematic outpatient prescription of NSAI.

Detailed Description

Renal colic are a frequent cause of consultation in the emergency departement (ED).

They count for approximatively 20% of patients presenting to the ED with severe acute onset abdominal pain.

For acute treatment of renal colics (RC), guidelines recommend the use of intravenous (IV) non-steroidal anti-inflammatory (NSAI) drugs in association with antalgics like Paracetamol or Morphine.

But the NSAID present many inconvenient and cannot be used in some type of patients; that's why the investigators investigated the use of other drugs, such as nebulised morphine, in the ED treatment of renal colics.

the NM has the adequacy of being quickest, more practical to use and more tolerated than the IV NSAID.

In this study, the investigators aim to assess the feasibility, efficacity and safety of nebulised morphine compared to intravenous NSAID in the treatment of RC.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Over 16 years old
  • Consenting to participate in the study
  • Diagnosis of renal colic matching flank pain / lumbar fossa sided with dipstick and / or imaging confirmed the diagnosis
  • VAS> 50% at consultation
Exclusion Criteria
  • Inability to assess pain VAS;
  • Pregnant or lactating woman;
  • Recognized renal disease (glomerular filtration rate <60ml/kg/1.73m2);
  • Known hepatic insufficiency;
  • Known or suspected allergy to NSAIDs, morphine
  • Peptic ulcer known;

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intravenous NSAIIV NSAIpatients received 100 mg of ketoprofen (NSAID) by IV root and in parallel 3 nebulisation of serum saline (SS) over 30 minutes.
Intravenous NSAINebulised Serum Salinepatients received 100 mg of ketoprofen (NSAID) by IV root and in parallel 3 nebulisation of serum saline (SS) over 30 minutes.
Nebulised MorphineNMpatients received 3 nebulisation of morphine (5 mg each) and in parallel 50 ml of SS by IV root over 30 minutes.
Nebulised MorphineIV Serum Salinepatients received 3 nebulisation of morphine (5 mg each) and in parallel 50 ml of SS by IV root over 30 minutes.
Primary Outcome Measures
NameTimeMethod
efficacity: VAS pain reduction5, 15, 30, 45 and 60 minutes

The effectiveness of treatment is defined by a decrease in the intensity of pain corresponding to a decrease of the VAS above 50% at 60 minutes compared to baseline.

Secondary Outcome Measures
NameTimeMethod
feasibility of the study: number of patients accepting the adhesion to protocolat base line and at 60 minutes

the feasibility is assessed by comparing the number of patients accepting the protocol to the total number of patients consulting for RC; and the number of patients that actually completed the protocol course (if above 50%, the protocol is considered feasable).

safety: side effects of treatment5, 15, 30, 45 and 60 minutes

the safety of treatment is evaluated by the occurence of side effects at any time of the protocol.

only major side effects (repeated vomiting, untolerated dizziness, conscience troubles, dyspnea and allergic reaction) are admitted to stop the protocol.

Trial Locations

Locations (1)

Hospital of Fattouma Bourguiba

🇹🇳

Monastir, Tunisia

© Copyright 2025. All Rights Reserved by MedPath